Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: A new measure of antiretroviral adherence?

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 3, 2013, Pages 260-266

  Adams, Jessica L ^a   Sykes, Craig ^a   Menezes, Prema ^b   Prince, Heather M A ^b   Patterson, Kristine B ^b   Fransen, Katrien ^c   Crucitti, Tania ^c   Baetselier, Irith De ^c   Damme, Lut Van ^d   Kashuba, Angela D M ^a,b  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

Adherence; Emtricitabine triphosphate; Intracellular concentrations; Peripheral blood mononuclear cells; Red blood cells; Tenofovir disphosphate; Total blood cells

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE TRIPHOSPHATE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; RALTEGRAVIR; TENOFOVIR DIPHOSPHATE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; BLOOD CELL; BLOOD SAMPLING; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MALE; MAXIMUM PLASMA CONCENTRATION; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER LAYER PACKED CELL; VIRUS LOAD; VIRUS STRAIN;

EID: 85027939499     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182794723     Document Type: Article

References (16)

1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
2. Baeten J, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367: 399-410.
3. Donnell D, Baeten J, Hendrix C, et al. Tenofovir disoproxil fumarate drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda. Paper presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA.Paper #30.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423-434.
5. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
6. Straka RJ, Rish JT, Benson SR, et al. Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy. 1997;17:126-132.
7. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of selfreport and electronic monitoring. Clin Infect Dis. 2001;33:1417-1423.
8. Truvada [Package Insert]. Foster City, CA: Gilead Sciences; 2011.
9. Hawkins T, Veikley W, St Claire RL, et al. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr. 2005;39:406-411.
10. Anderson PL, Kiser JJ, Garner EM, et al. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother. 2011;66:240-250.
11. Rower JE, Zheng JH, Klein BS, et al. Intracellular mono-, di- and triphosphate levels of tenofovir/emtricitabine in human peripheral blood mononuclear (hPBMC) vs. red blood cells (RBCs). Paper presented at 12th International Workshop on Clinical Pharmacology of HIV Therapy; April 13-15, 2011; Miami, FL. Abstract P-04.
12. Hoffman R, Benz EJ, Sanford SJ, et al. eds. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, PA: Churchill Livingston Elsevier; 2009.
13. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012;4:151ra125.
14. Durand-Gasselin L, Da Silva D, Benech H, et al. Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. Antimicrob Agents Chemother. 2007; 51:2105-2111.
15. Ray AS. Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Rev. 2005;7:113-125.
16. Castillo-Mancilla JR, Zheng JH, Rower JE, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure [published online ahead of print October 10, 2012. AIDS Res Hum Retroviruses. doi:10.1126/scitranslmed.3003174.